紫杉醇联合卡培他滨治疗晚期胃癌的疗效及安全性观察  

Efficacy and safety of paclitaxel combined with capecitabine in advanced gastric cancer

作　　者：米婷婷[1] 蒋冬 岳恺[3] 景天闯[1] MI Tingting;JIANG Dong;YUE Kai;JING Tianchuang(Department of Western Medicine,Nanyang Central Hospital,Nanyang 473000,He’nan,China;Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,He’nan,China;Department of Oncology,Nanyang Central Hospital,Nanyang 473000,He’nan,China)

机构地区：[1]南阳市中心医院西药药学部,河南南阳4730000 [2]南阳市中心医院消化内科,河南南阳4730000 [3]南阳市中心医院肿瘤内科,河南南阳4730000

出　　处：《癌症进展》2023年第9期985-988,共4页Oncology Progress

基　　金：南阳市科技计划项目(RKX069)。

摘　　要：目的 探讨紫杉醇联合卡培他滨治疗晚期胃癌的疗效及安全性.方法 将96例晚期胃癌患者根据治疗方式的不同分为对照组和观察组,每组48例.对照组患者采取卡培他滨治疗,观察组患者采取紫杉醇联合卡培他滨治疗.比较两组患者的疗效、肿瘤标志物水平、生活质量、不良反应发生情况及生存率.结果 观察组患者总缓解率、1年生存率均高于对照组,差异均有统计学意义(P﹤0.05).治疗后,两组患者糖类抗原19-9、癌胚抗原、糖类抗原72-4水平均较治疗前降低,且观察组患者糖类抗原19-9、癌胚抗原、糖类抗原72-4水平均低于对照组,差异均有统计学意义(P﹤0.05).治疗后,两组患者焦虑、胃部疼痛、呃逆、饮食受限评分均较治疗前降低,且观察组患者焦虑、胃部疼痛、呃逆、饮食受限评分均低于对照组,差异均有统计学意义(P﹤0.05).观察组患者脱发发生率高于对照组,差异有统计学意义(P﹤0.05).结论 将紫杉醇联合卡培他滨应用于晚期胃癌的治疗中,不仅能缓解患者的临床症状,还能改善其肿瘤标志物水平,改善生活质量,除脱发外,两组不良反应发生情况比较无显著差异,安全性较好,值得临床推广应用.Objective To analyze the efficacy and safety of paclitaxel combined with capecitabine in the treatment of patients with advanced gastric cancer.Method A total of 96 patients with advanced gastric cancer were divided into the control group(n=48,treated with capecitabine)and observation group(n=48,treated with paclitaxel+capecitabine)according to different treatment methods.The efficacy,levels of tumor markers,quality of life,incidence of adverse reactions and survival rate were compared between the two groups.Result The overall response rate and 1-year survival rate in the observation group were higher than those of the control group(P<0.05).After treatment,the levels of carbohydrate antigen 19-9,carcinoembryonic antigen,carbohydrate antigen 72-4 in both groups decreased,with lower levels in the observation group than those in the control group(P<0.05);the scores of anxiety,stomach pain,hiccup,dietary restriction in both groups decreased,with lower scores in the observation group than those in the control group(P<0.05);the incidence of hair loss in the observation group was higher than that in the control group(P<0.05).Conclusion Paclitaxel+capecitabine in the treatment of advanced gastric cancer can not only alleviate the clinical symptoms of patients,but also reduce tumor marker levels and improve quality of life,except for hair loss,there is no significant difference in adverse reactions between the two groups,and the safety is good,which is worthy of clinical promotion.

关 键 词：晚期胃癌 卡培他滨 紫杉醇 疗效 肿瘤标志物 生活质量 安全性 

分 类 号：R735.2[医药卫生—肿瘤]